Literature DB >> 32399727

Pulmonary embolism in neurocritical care-introduction of a novel grading system for risk stratification: the Frankfurt AMBOS score.

Daniel Dubinski1,2, Fee Keil3, Sae-Yeon Won4, Bedjan Behmanesh4, Kolja Jahnke5, Volker Seifert4, Christof Geisen6, Juergen Konczalla4, Christian Senft4.   

Abstract

Pulmonary embolism (PE) due to deep vein thrombosis is a complication with severe morbidity and mortality rates. Neurocritical care patients constitute an inhomogeneous cohort with often strict contraindications to conventional embolism treatment. The aim of the present study is to identify risk factors for pulmonary embolism for intensified risk stratification in this demanding cohort. In this retrospective analysis, 387 neurocritical care patients received computed tomography for clinical suspicion of PE (304 neurosurgical and 83 neurological patients). Analysed parameters included age, gender, disease pattern, the presence of deep vein thrombosis, resuscitation, in-hospital mortality, present anticoagulation, coronary artery disease, diabetes mellitus, smoking status, hypertension and ABO blood type. Computed tomography confirmed 165 cases of pulmonary embolism among 387 patients with clinical suspicion of pulmonary embolism (42%). Younger age (p < 0.0001), female gender (p < 0.006), neurooncological disease (p < 0.002), non-O blood type (p < 0.002) and the absence of Marcumar therapy (p < 0.003) were identified as significant risk factors for pulmonary embolism. On the basis of the identified risk factors, the AMBOS score system is introduced. Neurocritical care patients with high AMBOS score are at elevated risk for PE and should therefore be put under intensified monitoring for cardiovascular events in neurocritical care units.

Entities:  

Keywords:  Blood group; Deep vein thrombosis; Neurocritical care; Risk factor; Thromboembolism

Year:  2020        PMID: 32399727     DOI: 10.1007/s10143-020-01310-6

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  18 in total

1.  Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association.

Authors:  Michael R Jaff; M Sean McMurtry; Stephen L Archer; Mary Cushman; Neil Goldenberg; Samuel Z Goldhaber; J Stephen Jenkins; Jeffrey A Kline; Andrew D Michaels; Patricia Thistlethwaite; Suresh Vedantham; R James White; Brenda K Zierler
Journal:  Circulation       Date:  2011-03-21       Impact factor: 29.690

2.  Decision-making in a patient with cardiac arrest due to venous thromboembolism within 24 h after glioblastoma resection.

Authors:  D Dubinski; S-Y Won; M Bruder; M-T Forster; V Seifert; C Senft; J Berkefeld; J Mersmann
Journal:  Acta Neurochir (Wien)       Date:  2016-10-14       Impact factor: 2.216

Review 3.  ABO blood group and vascular disease: an update.

Authors:  Francesco Dentali; Anna Paola Sironi; Walter Ageno; Silvia Crestani; Massimo Franchini
Journal:  Semin Thromb Hemost       Date:  2013-12-31       Impact factor: 4.180

Review 4.  Absolute and Relative Contraindications to IV rt-PA for Acute Ischemic Stroke.

Authors:  Jennifer E Fugate; Alejandro A Rabinstein
Journal:  Neurohospitalist       Date:  2015-07

5.  Deep venous thrombosis and pulmonary embolisms in adult patients undergoing craniotomy for brain tumors.

Authors:  Kaisorn L Chaichana; Courtney Pendleton; Christopher Jackson; Juan Carlos Martinez-Gutierrez; Andrea Diaz-Stransky; Javier Aguayo; Alessandro Olivi; Jon Weingart; Gary Gallia; Michael Lim; Henry Brem; Alfredo Quinones-Hinojosa
Journal:  Neurol Res       Date:  2012-12-13       Impact factor: 2.448

Review 6.  International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.

Authors:  D Farge; P Debourdeau; M Beckers; C Baglin; R M Bauersachs; B Brenner; D Brilhante; A Falanga; G T Gerotzafias; N Haim; A K Kakkar; A A Khorana; R Lecumberri; M Mandala; M Marty; M Monreal; S A Mousa; S Noble; I Pabinger; P Prandoni; M H Prins; M H Qari; M B Streiff; K Syrigos; H Bounameaux; H R Büller
Journal:  J Thromb Haemost       Date:  2013-01       Impact factor: 5.824

7.  Influence of ABO blood type on the outcome after non-aneurysmal subarachnoid hemorrhage.

Authors:  Daniel Dubinski; Sae-Yeon Won; Bedjan Behmanesh; Sepide Kashefiolasl; Christof Geisen; Volker Seifert; Christian Senft; Juergen Konczalla
Journal:  Acta Neurochir (Wien)       Date:  2018-02-17       Impact factor: 2.216

8.  Prediction of pulmonary embolism in the emergency department: the revised Geneva score.

Authors:  Grégoire Le Gal; Marc Righini; Pierre-Marie Roy; Olivier Sanchez; Drahomir Aujesky; Henri Bounameaux; Arnaud Perrier
Journal:  Ann Intern Med       Date:  2006-02-07       Impact factor: 25.391

9.  Prospective multicenter evaluation of the pulmonary embolism rule-out criteria.

Authors:  J A Kline; D M Courtney; C Kabrhel; C L Moore; H A Smithline; M C Plewa; P B Richman; B J O'Neil; K Nordenholz
Journal:  J Thromb Haemost       Date:  2008-03-03       Impact factor: 5.824

10.  Emergent pulmonary embolectomy and advanced glioblastoma multiforme.

Authors:  Michael S Firstenberg; Danielle Blais; Erik Abel; Herbert B Newton; Juan Crestanello
Journal:  Case Rep Med       Date:  2010-12-20
View more
  3 in total

1.  A1B and BB blood group genotypes are risk factors for pulmonary embolism.

Authors:  Tatjana Kereš; Irena Jukić; Tomo Svaguša; Ingrid Prkačin; Jasna Bingulac-Popović; Matea Vinković; Ana Hećimović; Marcela Živković; Nikolina Parašilovac
Journal:  Wien Klin Wochenschr       Date:  2021-06-03       Impact factor: 1.704

2.  Incidence, risk factors and clinical course of pyogenic spondylodiscitis patients with pulmonary embolism.

Authors:  Daniel Dubinski; Sae-Yeon Won; Fee Keil; Bedjan Behmanesh; Max Dosch; Peter Baumgarten; Joshua D Bernstock; Volker Seifert; Thomas M Freiman; Florian Gessler
Journal:  Eur J Trauma Emerg Surg       Date:  2021-09-02       Impact factor: 2.374

3.  Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma.

Authors:  Daniel Dubinski; Sae-Yeon Won; Martin Voss; Fee Keil; Wolfgang Miesbach; Bedjan Behmanesh; Max Dosch; Peter Baumgarten; Joshua D Bernstock; Volker Seifert; Thomas M Freiman; Florian Gessler
Journal:  Neurosurg Rev       Date:  2021-04-26       Impact factor: 2.800

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.